Positron makes PET and PET-CT imaging systems focused primarily on cardiac imaging. These systems allow cardiologists to non-invasively diagnose coronary artery disease by measuring myocardial blood flow and perfusion — functional information that anatomical scans like CT or MRI cannot provide. Positron sells directly to hospitals, outpatient imaging centers, and cardiology practices in North America, and also offers rental and lease-to-own arrangements to reduce upfront capital barriers for smaller practices. Historically, nearly all revenue has come from servicing its installed base of PET systems rather than new equipment sales. Positron's business model combines equipment sales with multi-year service contracts covering maintenance, remote diagnostics, software updates, and clinical support. Positron's core commercial argument is price: the company positions its PET-CT systems well below what GE HealthCare, Philips, and Siemens charge, targeting smaller cardiology practices and mid-sized hospitals that have historically been priced out of PET-CT. Positron's growth strategy bets on the ongoing replacement of legacy SPECT systems with PET-CT, driven by superior diagnostic accuracy and higher Medicare reimbursement for PET studies. The company's next-generation Affinity PET-CT 4D 64-slice system, currently awaiting FDA clearance, is designed to expand beyond cardiology into oncology and neurology. Positron is a very small company with 10 full-time employees, and outsources manufacturing to Neusoft Medical Systems in China, which introduces single-source supply chain dependency. Positron holds exclusive North American distribution rights for Neusoft's PET and PET-CT systems.